Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome.
J Neuroimmune Pharmacol
; 16(1): 48-58, 2021 03.
Article
in English
| MEDLINE | ID: covidwho-1037278
ABSTRACT
Declared as a global public health emergency, coronavirus disease 2019 (COVID-19) is presented as a disease of the respiratory tract, although severe cases can affect the entire organism. Several studies have shown neurological symptoms, ranging from dizziness and loss of consciousness to cerebrovascular and neurodegenerative diseases. In this context, Guillain-Barré syndrome, an immune-mediated inflammatory neuropathy, has been closely associated with critical cases of infection with "severe acute respiratory syndrome of coronavirus 2" (SARS-CoV-2), the etiological agent of COVID-19. Its pathophysiology is related to a generalized inflammation that affects the nervous system, but neurotropism was also revealed by the new coronavirus, which may increase the risk of neurological sequel, as well as the mortality of the disease. Thus, considering the comorbidities that SARS-CoV-2 infection can promote, the modulation of purinergic signaling can be applied as a potential therapy. In this perspective, given the role of adenosine triphosphate (ATP) in neural intercommunication, the P2X7 receptor (P2X7R) acts on microglia cells and its inhibition may be able to reduce the inflammatory condition of neurodegenerative diseases. Finally, alternative measures to circumvent the reality of the COVID-19 pandemic need to be considered, given the severity of critical cases and the viral involvement of multiple organs.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Signal Transduction
/
Adenosine Triphosphate
/
Receptors, Purinergic
/
Guillain-Barre Syndrome
/
COVID-19
Type of study:
Etiology study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
J Neuroimmune Pharmacol
Journal subject:
Allergy and Immunology
/
Pharmacology
/
Neurology
Year:
2021
Document Type:
Article
Affiliation country:
S11481-020-09980-1
Similar
MEDLINE
...
LILACS
LIS